Abstract
It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.
MeSH terms
-
Anilides / chemistry
-
Anilides / metabolism
-
Anilides / therapeutic use
-
Biological Products / chemistry
-
Biological Products / metabolism
-
Biological Products / therapeutic use
-
Clinical Trials as Topic
-
Histone Deacetylase Inhibitors / chemistry*
-
Histone Deacetylase Inhibitors / metabolism
-
Histone Deacetylase Inhibitors / therapeutic use
-
Histone Deacetylases / chemistry
-
Histone Deacetylases / metabolism*
-
Humans
-
Hydroxamic Acids / chemistry
-
Hydroxamic Acids / metabolism
-
Hydroxamic Acids / therapeutic use
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / metabolism
-
Lymphoma / drug therapy
-
Lymphoma / pathology
-
Sulfhydryl Compounds / chemistry
-
Sulfhydryl Compounds / metabolism
-
Sulfhydryl Compounds / therapeutic use
Substances
-
Anilides
-
Biological Products
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Isoenzymes
-
Sulfhydryl Compounds
-
Histone Deacetylases